Register for our S/EIS Fund

Cambridge, UK, 05 August 2021: o2h Ventures is delighted to announce an investment into BiVictriX Therapeutics, an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience. 

BiVictriX is dedicated to applying a novel approach in developing safer and effective cancer therapies, by revolutionizing cancer therapy and making curative treatments available to all; By delivering a broad pipeline of proprietary, first-in-class Bi-Cygni® therapeutics to enable potentially higher dosing and more aggressive tumor eradication in patients, without causing harmful side effects.

The company also announced that it will be listed on the AIM market of the London Stock Exchange, raising £7.5m million from its initial public offering (IPO). With BiVictriX’s listing on AIM, 33-year-old CEO Tiffany Thorn becomes one of the youngest female CEOs of a UK-based publicly listed technology firm.

o2h Ventures (FRN 812245) is part of the o2h Group that has built an ecosystem to collaborate with early-stage businesses.  o2h Ventures was launched in 2018 to provide pre-seed and seed capital to companies in the biotech therapeutics space based in the UK.  To date the fund and pre-fund have invested into over 35 companies, several of which have now raised significant funds from overseas, listed and built game-changing drugs to benefit human health.

Sunil Shah, CEO of o2h Ventures, said: “We are very excited to invest in BiVictriX as their lead program looks to Target Acute Myeloid Leukemia, one of the most virulent and fast-growing cancers with horrific survival rates.  Their platform could not only provide highly specific drugs for AML but could also be applied to other cancer indications if successful. “

Tiffany Thorn, CEO and Founder of BiVictriX, said: “We are delighted that o2h Ventures were able to form part of the syndicate, they are a fund focused on drug discovery therapeutics and will be able to provide us with strong connections and advice as we scale our platform”.

About o2h Ventures:

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years.  o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information, please visit 

About the o2h human health knowledge-intensive EIS fund:

The o2h human health EIS fund is the first HMRC-approved knowledge-intensive fund in the UK. The fund focuses on investing in EIS companies covering novel drug discovery & AI, digital therapeutics, and enabling services.

To support the Government’s aim to strengthen and grow UK innovation, which was known to be capital and research-intensive, the EIS knowledge-intensive fund has been launched to pledge support to companies working in this space, providing them access to capital to develop their early novel ideas.

For more information, please visit

About BiVictriX Therapeutics:

Derived from frontline clinical experience, BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies. The Company, which was recently listed on the AIM of the London Stock Exchange (AIM: BVX), is pioneering a novel approach to cancer treatment based on its proprietary Bi-Cygni® therapeutics, potentially higher dosing and more aggressive tumor eradication without causing harmful side-effects to patients.

BiVictriX’s access to state-of-the-art techniques identifies combinations of cancer-specific targets for both solid and liquid tumors. The Company’s lead candidate is BVX001, designed to bring a genuinely novel immunotherapeutic approach to patients with acute myeloid leukemia (AML). 

BiVictriX is headquartered in Macclesfield, UK, with additional specialized laboratory facilities in St Asaph, Wales.

For more information, visit-

For further information, please contact:
o2h Ventures Ltd

Ajit Singh


BiVictriX Therapeutics

Tiffany Thorn, Founder & CEO



Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative

recent blogs

Comments are closed.